Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411839 | 1.00 | SIGMAR1 (0.47) | SIGMAR1TSHRCYP2C19CYP3A4TP53 | |
| SCHEMBL6472763 | 0.82 | SIGMAR1 (0.52) | SIGMAR1TSHRCYP2C19CYP3A4TP53 | |
| SCHEMBL23595063 | 0.78 | OPRL1 (0.45) | SIGMAR1TSHRCYP2C19CYP3A4TP53 | |
| SCHEMBL6422849 | 0.76 | SIGMAR1 (0.57) | SIGMAR1TSHRCYP2C19CYP3A4TP53 | |
| SCHEMBL2381131 | 0.73 | OPRL1 (0.57) | SIGMAR1TSHRCYP2C19CYP3A4TP53 | |
| SCHEMBL30976933 | 0.73 | — | — | |
| SCHEMBL18209383 | 0.72 | SIGMAR1 (0.55) | SIGMAR1TSHRCYP2C19CYP3A4TP53 | |
| SCHEMBL23595011 | 0.70 | OPRM1 (0.61) | SIGMAR1CYP3A4HSD17B10OPRL1 | |
| SCHEMBL6215031 | 0.69 | SIGMAR1 (0.57) | SIGMAR1TSHRCYP3A4ALDH1A1CYP2C9 | |
| SCHEMBL6777379 | 0.69 | SIGMAR1 (0.60) | SIGMAR1TSHRCYP2C19CYP3A4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2024179529-A1 | SUBSTITUTED TRICYCLIC DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海海雁医药科技有限公司 | 2024-09-06 | — | — | WO | disclosed |
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-04-27 | — | — | US | disclosed |
| WO-2021133563-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133563-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466829-B2 | Spirocyclic piperidine melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC2R, MC1R, MC3R | SIGMAR1 427/4885TSHR 102/4885CYP2C19 1659/4885 |
| US-20230126662-A1 | SPIROCYCLIC PIPERIDINE MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC2R, MC1R, MC3R | SIGMAR1 427/4885TSHR 102/4885CYP2C19 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.